Abbott and Tandem Diabetes Care announced on June 29, 2020 that they have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading continuous glucose monitoring (CGM) technology with Tandem’s innovative insulin delivery systems to provide more options for people to manage their diabetes. The companies first announced their intention to work together in October 2019, and this resulting agreement covers the technical development of device integration and associated commercial support activities.
When will your integrated system be available?
We haven’t shared commercial timing yet. It will be determined by a few different factors, including the timing for product integration work to be complete and for Abbott’s iCGM designation to be cleared for AID system compatibility.
